Progression of X-linked adrenoleukodystrophy under interferon-β therapy

Journal of Inherited Metabolic Disease

Volumn 20, Issue 1, 1997, Pages 59-66

  Korenke, G C ^a   Christen, H J ^a   Kruse, B ^a   Hunneman, D H ^a   Hanefeld, F ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; RECOMBINANT BETA INTERFERON; TRIOLEIN;

ADOLESCENT; ADRENOLEUKODYSTROPHY; CHILD; CLINICAL ARTICLE; FATIGUE; FEVER; HUMAN; INFLAMMATION; INJECTION PAIN; MALE; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; SYNTHESIS; X CHROMOSOME LINKAGE;

ADOLESCENT; ADRENOLEUKODYSTROPHY; ANTIMETABOLITES; CEREBROSPINAL FLUID PROTEINS; CHILD; DISEASE PROGRESSION; EVOKED POTENTIALS, VISUAL; FATTY ACIDS; HUMANS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; X CHROMOSOME;

EID: 0031055940     PISSN: 01418955     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005361607523     Document Type: Review

References (15)

1. Cappa M, Bertini E, del-Balzo P, Cambiaso P, Di-Biase A, Salvati S (1994) High dose immunoglobulin IV treatment in adrenoleukodystrophy. J Neurol Neurosurg Psychiatry 57: 69-70.
2. FNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 43: 655-661.
3. Hunneman DH, Hanefeld F (1988) Diagnose von peroxisomalen Erkrankungen-Erfahrungen mit einer empfindlichen massenfragmentographischen Bestimmung der sehr langkettigen Fettsäuren und der Phytansäure im Plasma. Monatsschr Kinderheilkd 136: 529.
4. Jacobs LD, Cookfair DL, Rudick RA et al (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39: 285-294.
5. Korenke GC, Hunneman DH, Kohler J, Stockler S, Landmark K, Hanefeld F (1995) Glyceroltrioleate/glyceroltrierucate therapy in 16 patients with X-chromosomal adrenoleukodystrophy/adrenomyeloneuropathy: effect on clinical, biochemical and neurophysiological parameters. Eur J Pediatr 154: 64-70.
6. Korenke GC, Christen H-I, Hunneman DH, Hanefeld F (1996) Failure of beta interferon therapy in X-linked adrenoleukodystrophy (Letter). Eur J Pediatr, 155: 833.
7. Kumar AJ, Rosenbaum AE, Naidu S et al (1987) Adrenoleukodystrophy: correlating MR imaging with CT. Radiology 165: 497-504.
8. Loes DJ, Hite S, Moser H et al (1994) Adrenoleukodystrophy, a scoring method for brain MR observations. Am J Neuroradiol 15: 1761-1766.
9. Moser HW, Moser AB, Smith KD et al (1992) Adrenoleukodystrophy: phenotypic variability and implications for therapy. J Inher Metab Dis 15: 645-664.
10. Naidu S, Bresnan MJ, Griffin D, Tool E-S, Moser HW (1988) Childhood adrenoleukodystrophy. Failure of intensive immunosuppression to arrest neurologic progression. Arch Neurol 45: 846-848.
11. Powers JM, Liu Y, Moser A, Moser H (1992) The inflammatory myelinopathy of adreno-leukodystrophy: cells, effector molecules, and pathogenetic implications. J Neuropathol Exp Neurol 51: 630-643.
12. Schaumburg HH, Powers JM, Raine CS et al (1975) Adrenoleukodystrophy. A clinical and pathological study of 17 cases. Arch Neurol 32: 577-591.
13. Stone LA, Frank JA, Albert PS et al (1995) The effect of interferon beta on blood brain barrier disruptions demonstrated by contrast enhanced magnetic resonance imaging in relapsing remitting multiple sclerosis. Ann Neurol 37: 611-619.
14. Stumpf DA, Hayward A, Haas R, Frost M, Schaumburg HH (1981) Adrenoleukodystrophy. Failure of immunosuppression to prevent neurological progression. Arch Neurol 38: 48-49.
15. Weinstock-Guttman B, Ransohoff RM, Kinkel RP, Rudick RA (1995) The interferons: biological effects, mechanism of action, and use in multiple sclerosis. Ann Neurol 37: 7-15.